The Metabolomics Service shared resource (Metabolomics) of the Rutgers Cancer Institute of New Jersey (CINJ) is a Cancer Center managed shared resource whose purpose is to enable state-of-the-art analysis of cancer metabolism. The past decade has seen a surge of interest in tumor metabolism, driven by the recognition that oncogenes up-regulate metabolism and that certain metabolites can themselves cause cancer (?oncometabolites?). The discovery of the best-established oncometabolite, 2-hydroxyglutarate, involved a central contribution from Joshua Rabinowitz, Director of this Metabolomics shared resource. The shared resource?s mission is two-fold: 1) to continue to push the frontiers of tumor metabolism measurement, enabling additional such scientific discoveries that significantly impact cancer diagnosis and therapy and 2) to provide CINJ members with easy, cost-effective access to these capabilities, thereby enhancing productivity across the consortium. To this end, the shared resource provides access to basic metabolism measurement capabilities, like oxygen consumption, which involve instruments that are readily shared (e.g., Seahorse). It also provides more advanced services, such as large-scale quantitative metabolite measurement by LC-MS. In addition, it develops and collaboratively applies cutting-edge metabolism measurement capabilities that are unique or available in only a handful of institutions world-wide (e.g. quantitative analysis of tumor-host metabolic interplay in vivo using isotope tracers). Building from informal collaborations that started in 2011, the consortium cancer center, with support from CCSG Developmental Funds, established a CCSG-supported developing shared resource for Metabolomics. This shared resource involved substantial investments by both Rutgers and Princeton Universities, in the form of multiple instruments purchased by each university. This shared resource not only met the existing need for metabolic analysis, but also encouraged investigators, through a variety of programmatic platforms, to pursue cancer metabolism research. MSR, Page 1 of 1; DRAFT 1/18/18 8:28 AM !

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA072720-22
Application #
10112866
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-03-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
22
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803
Jang, Thomas L; Patel, Neal; Faiena, Izak et al. (2018) Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 124:4010-4022
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
Patrizii, Michele; Bartucci, Monica; Pine, Sharon R et al. (2018) Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol 8:23
Zloza, Andrew (2018) Viruses, bacteria, and parasites - oh my! a resurgence of interest in microbial-based therapy for cancer. J Immunother Cancer 6:3
CeliĆ -Terrassa, Toni; Bastian, Caleb; Liu, Daniel et al. (2018) Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nat Commun 9:5005
George, Blessy; Joy, Melanie S; Aleksunes, Lauren M (2018) Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Exp Biol Med (Maywood) 243:272-282
Paratala, Bhavna S; Chung, Jon H; Williams, Casey B et al. (2018) RET rearrangements are actionable alterations in breast cancer. Nat Commun 9:4821
Jian-Yu E; Graber, Judith M; Lu, Shou-En et al. (2018) Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. Curr Med Chem 25:2595-2607

Showing the most recent 10 out of 775 publications